
    
      The objective is to assess efficacy endpoints in comparison with 0.1% BM ophthalmic solution,
      prior to investigation of the efficacy and safety of 0.05% DFBA ophthalmic emulsion in the
      treatment of postoperative intraocular inflammation.
    
  